At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Nivolumab 480 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Uterine Cancer and 6 related conditions. Completed, enrolled 35 participants across 8 sites.
Detailed Summary
The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma, Undifferentiated Sarcoma, High Grade Endometrial Stromal Sarcoma, Clear Cell Carcinoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartAug 2017
First PostedAug 2017
Primary CompletionApr 2024
TodayJul 2026
First PostedAug 7, 2017
Enrollment StartAug 3, 2017
Primary CompletionApr 1, 2024
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 8.9 years ago
Interventions
Nivolumabdrug
Nivolumab 480 mg IV once every 4 weeks